http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111514158-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate | 2020-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111514158-B |
| titleOfInvention | Application of timosaponin N in preparation of medicine for preventing and treating pulmonary fibrosis |
| abstract | The invention relates to an application of timosaponin N in preparing a medicament for preventing and treating pulmonary fibrosis. In the embodiment of the invention, timosaponin N can obviously improve the body weight and the lung index of a bleomycin pulmonary fibrosis model rat, and obviously reduce biochemical indexes closely related to pulmonary fibrosis, such as the content of hydroxyproline in lung tissues and the levels of TGF-beta and TNF-alpha in alveolar lavage fluid. In addition, the combination of timosaponin N with pirfenidone further synergistically improves the above-mentioned indications associated with pulmonary fibrosis. Therefore, the timosaponin N or the timosaponin N combined with pirfenidone can effectively improve the pulmonary fibrosis degree of rats with pulmonary fibrosis models, has a prospect of developing anti-pulmonary fibrosis drugs, and has important social and economic benefits. |
| priorityDate | 2020-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.